[{"id":"f3638445-1962-425f-bf99-dd0895925929","acronym":"NCI-2018-00115","url":"https://clinicaltrials.gov/study/NCT03428802","created_at":"2021-01-18T16:54:49.559Z","updated_at":"2024-07-02T16:36:00.195Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability","source_id_and_acronym":"NCT03428802 - NCI-2018-00115","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" PD-L1 • BRCA1 • BRCA2 • POLE • POLD1","pipe":" | ","alterations":" BRCA1 mutation • POLD1 mutation • POLE mutation + POLD1 mutation","tags":["PD-L1 • BRCA1 • BRCA2 • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • POLD1 mutation • POLE mutation + POLD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/08/2018","start_date":" 03/08/2018","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2023","study_completion_date":" 10/02/2023","last_update_posted":"2022-11-18"},{"id":"0a5b61b3-7667-454c-b61f-affb10bb9e77","acronym":"3CI Study","url":"https://clinicaltrials.gov/study/NCT04500548","created_at":"2021-01-18T21:33:32.102Z","updated_at":"2024-07-02T16:36:04.140Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","source_id_and_acronym":"NCT04500548 - 3CI Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression","tags":["TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 06/21/2022","study_completion_date":" 06/21/2022","last_update_posted":"2022-09-12"}]